Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading…
Transcript

Genentech - Roche

Market Analysis

Overview of Genentech

Evolution of Bio tech

-Dr. Richard Scheller- President of R&D at Genentech.

-Genentech, bought by Roche Group, looking to revolutionize personalized medicine.

-Heavy focus on stage II and stage III of biotechnology medical research.

-Looked at core capabilities of

"strategic balance between

generating novel therapies and

pursuing further commercial

discoveries."

  • Commercialization of scientific bio tech is an attractive and powerful business model.

  • 3 main components of biotechnology:

1. Disruptive technology

2. Venture Capital

3. Public equity markets

  • Most all breakthroughs and research were at universities and institutes, but lacked funding commercialization skills.

  • Partnered with venture capitalists created "biopharmaceuticls" or "prescription drugs."

Genentech

History

  • Founded in 1976. Recognized the potential in newly discovered recombinant DNA.

  • Genentech's first aim was to "leverage the newly discovered rDNA technology to develop a new generation of therapeutics.

  • Focused on critical medical conditions in oncology, immunology, and tissue growth and repair.

  • Incredible growth and profit potential. In 2008: $13.4 billion in revenues. Just 3 years earlier, in 2005, had $6.6 billion in profits.

Birth of Biotech

Industry Landscape

  • Pharmaceutical uses plant and chemical elements to make medicines that cure or manage diseases, and protect us from infection.

  • Biotech involves the use of cellular and bio molecular processes for health care applications.

  • The "specificity of DNA" allows biotech to "address specific medical needs with fewer side-effects.

  • The rearranging and manipulation of this DNA allows this new technology to be very controlled and directed.

  • 1980-First real patent for Biotech by U.S. Patent Office for recombinant DNA.

  • Essentially, biotech is revolutionizing drug development, design, and creation of prescription drugs.

Biotech Growth and Genentech competitors

Industry model

Research & Development pipeline

Quadruple Bottom Line

People

  • Universal Health Care
  • Research Volunteers
  • Treatment Efficacy

Planet

  • Commercial production
  • Genetically modified organs, plants and animals

Profits

  • 25% R&D largest of any industry
  • Return on equity
  • Increasing shareholder value

Politics

  • Comparative Effective Research, US Congress 2009
  • BioGenerics
  • BioSimilars, 2010

Bio-pharmaceutical Key Success Factors

  • Product
  • Pipeline Size
  • Breakthrough Research
  • Financial Resources
  • Capital Investments
  • Private and Public
  • Political Climate
  • Regulatory Compliance
  • Perpetual Patents
  • Industry Infrastructure
  • Personalized Solutions
  • Channels of Distribution
  • Human Resources
  • Entrepreneurial
  • Commitment
  • Team oriented
  • Networking
  • University Partners
  • Outsourced Teams
  • BigPharma
  • Company Climate
  • Mergers and Acquisitions
  • Globalization

Genentech

5 Forces

Potential Entrants

  • Individual Researchers
  • VC groups

Buyers

  • Regulations
  • Big Pharma

Existing

Rivals

Suppliers

  • Universities
  • Biolabs
  • R&D tech

Substitutes

  • Biosimilars
  • R&D Costs

Jason Watters & Miguel Vasquez

Learn more about creating dynamic, engaging presentations with Prezi